Resource
Consumer Brief Supporting NY Attorney General In Alzheimer's Drug Case
In December, a U.S. judge upheld the New York Attorney General's request for an injunction requiring the powerful Big Pharma company Actavis to continue marketing a lower-cost version of its Alzheimer's drug Namenda, instead of using a "product-hopping" scheme to move consumers to a newer but virtually identical version that would enjoy monopoly protection until 2029, making it unlikely that lower-cost generic alternatives could successfully enter the market. We joined other leading groups, including Consumers Union and Public Citizen, in a friend-of-the-court brief to the U.S. Second Circuit Court of Appeals supporting General Eric Schneiderman's defense against Actavis in its appeal. Our brief is attached.
Resource file download
Consumer Brief Supporting NY AG in Alzheimer's Drug Case
Support Us
Your donation supports U.S. PIRG’s work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.